Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

Sandbox escape vulnerability in vm2, used by nearly 900 NPM packages, allows attackers to bypass security protections and execute arbitrary code. A critical vulnerability has been patched in vm2, a ...

A critical sandbox escape vulnerability has been disclosed in the popular vm2 Node.js library that, if successfully exploited, could allow attackers to run arbitrary code on the underlying operating ...

A critical-severity vulnerability in the vm2 Node.js sandbox library, tracked as CVE-2026-22709, allows escaping the sandbox and executing arbitrary code on the underlying host system. The open-source ...

Forbes contributors publish independent expert analyses and insights. Technology journalist specializing in audio, computing and Apple Macs. This voice experience is generated by AI. Learn more. This ...

Dahl highlighted that software engineering isn't disappearing — it's transforming. It has been a while since tech leaders have cautioned developers about AI taking over the task of writing codes. Now ...

Node.js has released updates to fix what it described as a critical security issue impacting "virtually every production Node.js app" that, if successfully exploited, could trigger a denial-of-service ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in The Trade Desk Inc (Symbol: TTD), where a total of 69,953 contracts have traded so far, ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...